VC: Novexel gains $64.8M in second round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Novexel [1]
Paris

$64.8M
Second

Edmond de Rothschild Investment Partnersd

Novexel is advancing four anti-infectives in its pipeline. 

Movetis [2]
Belgium

$63.5M
First

Sofinnova Partners/Life Sciences Partners

Movetis will use the funds to complete development and filing of its lead phase III compound, continue clinical development of three other products and move four additional products into pre-clinical and phase I clinical development.

Fluidigm [3]
South San Francisco

$37M
Fifth

Wasatch Advisors

Fluidigm will use the capital to boost sales and marketing of its BioMark system and TOPAZ system for protein crystallization and to develop new products in the pipeline.

Variation Biotechnologies [4]
Ottawa, Canada

$35.7M
First

Clarus Ventures

The money goes to advance the company's Variosite vaccine platform into clinical development, beginning with lead vaccine candidates for influenza.

Proprius Pharmaceuticals [5]
San Diego

$11M - $17M
First

Atlas Venture

Much of that will go to develop Indaflex, a topical non-steroidal anti-inflammatory drug formulation in Phase II clinical development for osteoarthritis of the knee.  

Gentiae Clinical Research [6]
San Bruno, CA

$16M

Bay City Capital

Gentiae provides comprehensive cardiac assessment services for clinical trials.

Juvaris BioTherapeutics [7]
Pleasanton, CA

$6M
First

Kleiner Perkins Caufield & Byers Pandemic & Biodefense Fund

The funds will enable Juvaris to advance its lead vaccine products for influenza and pneumonia indications to clinical trials. The company will also pursue immunotherapy products for Hepatitis B and Biodefense applications.

F-Star [8]
Vienna, Austria

$1.94M
Seed

Atlas Venture

The money goes to optimize its modular antibody technology, to advancing initiatives to partner its research and development platform, and to commencing the development of a proprietary product pipeline.